The increasing use of GLP-1 agonists in hospital settings requires special attention to gastrointestinal symptoms and perioperative risk. These effects can compromise food intake, clinical recovery, and surgical safety. Nutritional management must be individualized, focusing on digestive tolerance and multidisciplinary integration.

Gut health in the hospital environment goes beyond the control of diarrhea and constipation. Dysbiosis and increased intestinal permeability directly impact immunity, infectious risk, and clinical recovery.

Malnutrition is a common condition in cancer patients and is strongly associated with worse clinical outcomes, such as increased treatment toxicity, length of hospitalization, and mortality.

Literally, probiotics are defined as living organisms that, when used in adequate doses, confer clinical benefits to the host/patient.